STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.77 CNY | -4.38% |
|
+1.35% | -33.37% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Staidson (Beijing) Biopharmaceuticals Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of innovative therapeutic medicine with independent intellectual property rights including protein medicine, genetic medicine and chemical medicine, among others. The Companyâs products include mouse nerve growth factor for injection, which are applied in the neuroprotection and treatment of nerve injuries, as well as polyethylene glycol electrolyte powders, which are applied in the bowel cleansing and treatment of constipation. The Company mainly distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -33.37% | 468M | |
| -2.61% | 88.47B | |
| +3.55% | 40.71B | |
| -14.40% | 32.43B | |
| +55.89% | 24.28B | |
| -15.96% | 15.52B | |
| -41.29% | 12.17B | |
| -15.50% | 12.01B | |
| -11.75% | 12B | |
| +7.87% | 8.87B |
- Stock Market
- Equities
- 300204 Stock
- News Staidson (Beijing) BioPharmaceuticals Co., Ltd.
- Staidson Forms R&D Deal With Germany’s InflaRx
